Varex Imaging (VREX) Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary
Event summary combining transcript, slides, and related documents.
Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary
17 Mar, 2026Macroeconomic and geopolitical environment
Business remains stable despite geopolitical tensions and tariff fluctuations; minimal direct impact from Middle East events and stable order intake rates observed so far.
Healthcare demand and hospital capital budgets remain resilient, with no significant changes in customer sentiment or capital expenditure domestically or in the EU.
Industrial segment shows flat to positive trends, especially in security, with increased inquiries and urgency.
Tariffs and supply chain strategy
Tariff situation has stabilized after initial disruptions; inventory purchased at higher tariffs will take 4-5 months to work through, after which a marginal gross margin uplift is expected.
Ongoing diversification of supply chain, including expansion in India, and continued price adjustments to customers to mitigate tariff impacts.
Expectation that tariff volatility will persist, with Section 301 developments being closely monitored.
Regional market dynamics
China’s healthcare market has normalized to steady, secular growth, with domestic OEMs gaining market share through competitive tenders.
No material supply chain risks identified for critical materials in the X-ray domain; competitive pressure on global OEMs in China remains high.
Japan shows no growth, while Europe remains stable.
Latest events from Varex Imaging
- Stable demand, India expansion, and photon counting tech position for growth amid policy uncertainty.VREX
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - All board nominees, executive pay, and auditor ratification were approved by stockholders.VREX
AGM 202612 Feb 2026 - Revenue up 5% to $210M, 90% EPS growth, strong industrial momentum, and positive Q2 outlook.VREX
Q1 202611 Feb 2026 - Revenue beat guidance, but a $93.9M goodwill impairment led to a GAAP net loss.VREX
Q3 20253 Feb 2026 - Photon counting tech, China recovery, and debt reduction drive 2025 outlook amid trade risks.VREX
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Revenue down 9.9% year-over-year; Medical weak, Industrial up, Q4 outlook cautious.VREX
Q3 20242 Feb 2026 - Photon counting and industrial innovation drive growth amid medical market headwinds and China recovery.VREX
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Investments in India, photon counting, and cargo systems set up strong multi-year growth.VREX
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - Q4 revenue was $206M, with strong Industrial results and a 12% Medical segment decline.VREX
Q4 202413 Jan 2026